-
ASAM Joins Coalition Letter in Support of the Bipartisan Health Care Stabilization Act of 2017
ASAM joined a coalition letter expressing support for the Bipartisan Health Care Stabilization Act of 2017 and leading bipartisan efforts to provide stabilization to the health insurance marketplace.Full story -
ACA and ASAM release Joint Public Correctional Policy on the Treatment of Opioid Use Disorders for Justice Involved Individuals.
The statement includes recommendations to support correctional policy makers and correctional healthcare professionals in providing evidence-based care to those in their custody or under their supervision who have an opioid use disorder.Full story -
ASAM Applauds FDA's Approval of New Monthly Injectable Buprenorphine Formulation
On December 30, 2017, the Food and Drug Administration (FDA) announced the approval of Sublocade, a monthly formulation of buprenorphine subcutaneous injection for treatment of opioid dependence. This injection is the first monthly formulation of buprenorphine to be approved by the FDA.Full story -
ASAM and NJSAM Submit Letters of Support for Legislation to Allow NPs and PAs to Prescribe Buprenorphine for Addiction Treatment
ASAM and the New Jersey Society of Addiction Medicine (NJSAM) submitted letters of support with a recommended revision for A4910 and S3272, legislation that would align state law with federal law to allow NPs and PAs to prescribe buprenorphine for addiction treatment.Full story -
ASAM Joins Group Letter Supporting Continued Funding for ONDCP
ASAM signed onto a letter sent to the Senior Advisor to the President regarding the Office of Management and Budget's (OMB) proposed budget which would slash funding for the Office of National Drug Control Policy (ONDCP) and drug control program funding.Full story -
ASAM submits comments to FDA on the REMS Blueprint and Mandatory Prescriber Education
ASAM submitted comment letters to the Food and Drug Administration (FDA) with recommendations regarding its proposed Blueprint for the extended-release, long-acting (ER/LA) Opioid Risk Evaluation and Mitigation Strategy (REMS) training as well as whether such training should be mandatory for all ER/LA opioid prescribers.Full story -
ASAM Issues Letter of Support for Legislation to Permit Medicare Coverage of Methadone in Outpatient Treatment Settings
ASAM issued a letter of support for H.R. 4097, the Medicare Beneficiary Opioid Addiction Treatment Act, sponsored by Rep. Richard Neal. This legislation would modify the Medicare Part B program to permit Medicare coverage of methadone as an outpatient treatment for addiction. Currently, Medicare only covers methadone for inpatient use when used for addiction and is contrary to ASAM’s policy recommending that all public and private payers provide insurance coverage for the treatment of opioid addiction.Full story -
ASAM Lead Coalition Letter Voicing Concern About Comments by HHS Secretary Tom Price
ASAM led a coalition letter to HHS Secretary Tom Price expressing concern about comments he made in West Virginia suggesting that some forms of medication for opioid use disorder are superior to others, and that some are just replacing one opioid with another. The letter emphasizes how all three medications r approved by the FDA to treat opioid use disorder and are safe, effective, and help patients enter and sustain recovery and regain control of their lives.Full story -
ASAM applauds the Surgeon General’s release of Facing Addiction in America: The Surgeon General’s Spotlight on Opioids
Newest update on opioid addiction- calls for a cultural shift in the way Americans talk about the opioid overdose crisis and recommends actions that can prevent and treat opioid use disorder and promote recovery.Full story
